Akorn, Inc. / VPI Holdings Corp. (VersaPharm Incorporated)

Specialty generics across dermatology, tuberculosis (rifampin), and hemophilia

8K US cases/yr · $700M VersaPharm addressable IMS market value (pipeline + marketed)

Disease Overview

Specialty injectable and topical generics serving small but high-barrier US markets - notably injectable rifampin (one of only three FDA-approved generic suppliers at deal time, used for active and latent TB), topical dermatology agents, and clotting-factor adjuncts for hemophilia. These categories combine limited competition with steady reimbursement, attractive to roll-up generics platforms.

Competitive Landscape

Specialty generics in 2014 was in roll-up mode: Hikma, Mylan, Endo (Par/Qualitest), and Lannett were aggressively buying ANDAs in injectable and dermatology niches that had thin competition and pricing power, while Hi-Tech Pharmacal (which Akorn had bought in 2014) anchored ophthalmic and topical platforms. VersaPharm's appeal was its position as one of only three FDA-approved generic injectable rifampin suppliers - a fact the FTC focused on, ultimately requiring divestitures to clear the deal. The 11 ANDAs and 20+ product pipeline carried an addressable IMS market value above $700M, expected to add $90-100M in annual revenue and $0.10-$0.12 EPS for Akorn. The deal essentially doubled Akorn's revenue and product portfolio in roughly 12 months, layered on top of the Hi-Tech integration. What it changed: VersaPharm gave Akorn TB and hemophilia footholds outside its historical ophthalmic/injectable base, broadening therapeutic coverage at the moment generic pricing was about to enter a multi-year compression cycle that ultimately destabilized Akorn (Fresenius Kabi terminated its 2017 acquisition of Akorn citing data integrity issues).